Split pattern (1O1G1F) | Single orange (1O1F) | LCNG | HCNG | |
---|---|---|---|---|
ER−/PR−/HER2− (n = 61) | 1 (2 %) | 12 (1–3 %) | 39 (6–68 %) | 1 (13 %) |
ER−/PR−/HER2+ (n = 15) | 0 (0 %) | 3 (1–3 %) | 12 (10–68 %) | 1 (8 %) |
ER+/PR±/HER2− (n = 37) | 3 (2–3 %) | 7 (1–12 %) | 21 (6–69 %) | 2 (6–11 %) |
ER+/PR+/HER2+ (n = 20) | 0 (0 %) | 1 (1 %) | 6 (6–91 %) | 0 (0 %) |
Inflammatory breast carcinoma (n = 13) | 3 (2–3 %) | 3 (5–12 %) | 10 (9–69 %) | 3 (6–13 %) |